BUY NOW For Sale 70%!
buy viagra

Cipro actions



Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel


Drugs & Diseases

Brand and Other Names:Flagyl, Flagyl ER, more...Flagyl IV RTU

  • Email
  • Feedback

Dosing & Uses


Dosage Forms & Strengths


  • 375mg


  • 250mg
  • 500mg

tablet, extended-release

  • 750mg

infusion solution

  • 500mg/100mL


Anaerobic Bacterial Infections

Loading dose: 15 mg/kg IV; not to exceed 4 g/day 

Maintenance dose: 7.5 mg/kg PO/IV (over 1 h) q6hr x 7-10 days (or 2-3 weeks if severe)

Sexually Transmitted Disease

Prevention following sexual assault

2 g PO as a single dose; 3-drug regimen that also includes ceftriaxone or cefixime, PLUS azithromycin or doxycycline (CDC STD guidelines, 2010)

Bacterial Vaginosis

Nonpregnant women

  • 500 mg PO BID x 7 days, OR
  • 2 g PO qDay single dose, OR
  • Extended-release: 750 mg PO qDay x 7 days

Pregnant women

  • 500 mg PO BID x 7 days, OR
  • 250 mg PO TID x 7 days

Colorectal Surgical Infection

Prophylaxis; start after mechanical bowel preparation the afternoon and evening before surgery

1 g PO q6-8hr for 3 doses

15 mg/kg IV over 30-60 min; complete approximately 1 hr before surgery; may administer 7.5 mg/kg IV over 30-60 min at 6 and 12 hr after initial dose for maintenance; discontinue within 12 hr after surgery


250 mg PO q8hr for 7 days; alternatively, 375 mg PO q12hr for 7 days

2 g PO qDay single dose; alternatively, 1g PO q12hr for 2 doses


500-750 mg PO q8hr for 5-10 days

Giardiasis (Off-label)

500 mg PO q12hr for 5-7 days

Gardnerella Infection

Immediate release: 500 mg PO q12hr

Extended-release: 750 mg PO qDay for 7 days; take on empty stomach

Helicobacter Pylori Infection (Off-label)

250-500 mg PO QID in combination with tetracycline (500 mg) and bismuth subsalicylate (525 mg) x 14 days

Nongonococcal Urethritis (Off-label)

2 g PO qDay single dose with erythromycin (500 mg QID) or erythromycin ethylsuccinate (800 mg QID) x 7 days

Pelvic Inflammatory Disease (Off-label)

500 mg PO q12hr for 14 days in conjunction with ofloxacin or levofloxacin

Pouchitis (Orphan)

Orphan indication sponsor

  • Formac Pharmaceuticals, NV; Gaston Geenslaan 1; Belgium

Crohn Disease (Orphan)

Topical treatment of active perianal Crohn disease

Orphan indication sponsor

  • Braintree Laboratories, Inc; 60 Columbian Street West; PO Box 850929; Braintree, MA 02185-0929

Perioral Dermatitis (Orphan)

Orphan indication sponsor

  • Galderma Laboratories, Inc; P.O. Box 331329; Fort Worth, TX 76163

Dosage Forms & Strengths


  • 375mg


  • 250mg
  • 500mg

tablet, extended-release

  • 750mg

infusion solution

  • 500mg/100mL


Neonatal (<28 Days) Anaerobic Infection

<1.2 kg

  • 7.5 mg/kg IV/PO q48hr 

<7 days

  • 1.2-2 kg: 7.5 mg/kg IV/PO qDay
  • >2 kg: 15 mg/kg/day IV/PO divided q12hr

>7 days

  • 1.2-2 kg: 15 mg/kg/day IV/PO divided q12hr
  • >2 kg: 30 mg/kg/day IV/PO divided q12hr

Infants and Children

  • 30 mg/kg/day PO/IV divided q6hr; not to exceed 4 g/day

Clostridium Difficile Colitis

30 mg/kg/day IV/PO divided q6hr IV/PO for 7-10 days (American Academy of Pediatrics) 


35-50 mg/kg PO divided q8hr for 10 days 


15 mg/kg/day IV/PO divided q8hr for 5 days 


< 45 kg body weight: 15 mg/kg/day IV/PO divided q8hr for 7 days; not to exceed 2 g/day 

Helicobacter Pylori-Associated Peptic Ulcer Disease (Off-label)

With amoxicillin and bismuth subsalicylate: 15-20 mg/kg/day PO divided q12hr for 4 weeks 


Interaction Checker

Enter a drug name and metronidazole

No Results

 activity indicator 

No Interactions Found

Interactions Found


Serious - Use Alternative

All Interactions Sort By: Severity Name
 activity indicator 



Adverse Effects

Frequency Not Defined

Appetite loss








Dark urine

Disulfiram-type reaction with ethanol

Furry tongue



Metallic taste







Aseptic meningitis

Optic neuropathy

Stevens-Johnson syndrome

Toxic epidermal necrolysis

Decreased libido

Postmarketing Reports

Dyspareunia, proctitis, fleeting joint pains that may resemble serum sickness, Crohn’s disease, hiccup, psychosis





Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)

Pregnancy, 1st trimester (controversial)

Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy


Encephalopathcy, seizures, aseptic meningitis, and neuropathies reported with increase in dose and chronic therapy

Superinfection may occur with prolonged use

Severe hepatic impairment; administer lower doses with caution

Use with caution; potential accumulation in end stage renal disease; supplemental doses may be needed in patients receiving hemodialysis

Use with caution in history of blood dyscrasias, heart failure, hepatic failure, H. pylori infection, renal impairment

Avoid alcohol while taking medication and for at least 1 day after discontinuation

Antiandrogen: May cause gynecomastia

Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with Metronidazole Injection and requires treatment with a candicidal agent



Pregnancy & Lactation

Pregnancy category: B


Excreted in human milk; not recommended

Following PO administration, concentrations in human milk are similar to concentrations in plasma

Potential for tumorigenicity shown in animal studies; a decision should be made whether to discontinue nursing or to discontinue metronidazole; breastfeeding women may choose to pump and discard milk for the duration of therapy and for 24 hours after therapy ends and to feed her infant stored human milk or formula

Study Data

There are published data from case-control studies, cohort studies, and 2 meta-analyses that included more than 5000 pregnant women who used metronidazole systemically during pregnancy

Many studies included first trimester exposures

One study showed an increased risk of cleft lip, with or without cleft palate, in infants exposed to metronidazole in utero; however, these findings were not confirmed

In addition, actions more than 10 randomized, placebo-controlled clinical trials that together enrolled over 5000 pregnant women assessed the possible effect of systemic antibiotic treatment (including with metronidazole) for bacterial vaginosis on the incidence of preterm delivery; most studies did not show an increased risk of congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy

Three studies conducted to assess the risk of infant cancer following systemic metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited

Pregnancy Categories





Mechanism of Action

Inhibits nucleic acid synthesis by disrupting DNA and causing strand breakage; amebicidal, bactericidal, trichomonacidal


Bioavailability: 80% absorption from GI tract (PO)

Protein binding (<20%)

Peak serum time: 1-2 hr


Widely distributed; similar pattern for PO and IV



Enzymes inhibited: Hepatic CYP2C9


Half-life: 25-75 hr (neonates); 8 hr (others); prolonged in patients with hepatic impairment

Excretion: Urine (77%); feces (14%)




IV Incompatibilities

Some drugs may be incompatible with reconstituted solution from powder (which contains metronidazole HCl) but compatible with RTU IV solution (which contains metronidazole), and vice versa

Additive: Aztreonam, cefepime(?), ciprofloxacin (may be compatible with RTU solution), dopamine, meropenem

Y-site: Amphotericin B cholesteryl sulfate, aztreonam, filgrastim, meropenem, warfarin

IV Preparation

Reconstitute powder with 4.4 mL sterile water for injection, bacteriostatic water for injection, NS, or bacteriostatic NS to a final concentration of 100 mg/mL (pH 0.5-2)

Further dilute in glass or plastic container to no more than 8 mg/mL with NS, D5W, or LR

Neutralize with approximately 5 mEq NaHCO3 per 500 mg metronidazole; final pH 6-7

No dilution or buffering necessary for ready-to-use IV solution

IV Administration

Infusion only

Avoid contact between drug and aluminum in infusion set (less critical for RTU infusion solution containing metronidazole rather than metronidazole HCl)


Store at 15-30°C

Protect from light




loading Pricing and Images



Patient Handout

activity indicator
activity indicator




FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Non-Medicare Plans Medicare Plans



Additional Offers


What would you like to print?


BUY NOW For Sale 70%!
buy viagra

Ciprofloxacin Drug Interactions - m Clofazimine renal dose cipro

Cipro actions 12 Common Sexually Transmitted Diseases (STDs) In
Cipro actions Themenauswahl - LE CAP
Cipro actions Village of Suffern
Cipro actions Liver Function Tests for Hepatitis C: Why It s Done, Results
Cipro actions Glucovance (glyburide/metformin) - MedicineNet
Cipro actions Hotel Kaya Artemis Resort - Cipro Nord Il Viaggio - Il Viaggio Biz
Cipro actions Reactive Airway Disease Treatment - Respiratory Disorders
Cipro actions Online Pharmacy Store, Medicine Information - Drug Infosys
Reno's Fastest Taxi Cab, Call a Cab - Reno Sparks Cab Co PZN Arzneimittelname Festbetrag_ab_ PIROXICAM Antibiotics for Klebsiella Pneumoniae M ECV: News Archiv Embryotox - Arzneimittelsicherheit in Schwangerschaft CIPRO XR(ciprofloxacin extended-release tablets)
BUY NOW For Sale 70%!
buy viagra